3,829 results match your criteria Carcinoma in Situ of the Urinary Bladder


Methylation study of the Paris system for reporting urinary (TPS) categories.

J Clin Pathol 2020 Jun 11. Epub 2020 Jun 11.

Department of Urology, Catholic University of the Sacred Heart, "Agostino Gemelli" School of Medicine, Rome, Italy.

Aims: Bladder EpiCheck is one of several urinary tests studied to identify bladder tumours and analyses 15 methylation biomarkers determining bladder cancer presence on the basis of methylation profile.

Methods: 374 patients diagnosed with high-grade non-muscle invasive bladder cancer were treated and followed for 1 year with voided urine cytology and white-light cystoscopy and biopsies according to European Association of Urology Guidelines. 268 cases were diagnosed with high-grade papillary carcinoma, while 106 cases were carcinoma in situ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2020-206633DOI Listing

Yolk sac tumor differentiation in urothelial carcinoma of the urinary bladder: a case report and differential diagnosis.

Diagn Pathol 2020 Jun 3;15(1):68. Epub 2020 Jun 3.

Department of Pathology, Hospital Universitari de Bellvitge, [Bellvitge Biomedical Research Institute] IDIBELL, Feixa Llarga S/N., 08907. L'Hospitalet de Llobregat, Barcelona, Spain.

Background: Yolk sac tumor (YST) is a germ cell neoplasm that arises predominantly in the gonads, but can also derive from somatic neoplasms in extragonadal locations. These latter cases have been documented in several organs, although reports from the urinary tract are limited. To our knowledge, this is the first report of a bladder urothelial carcinoma with a predominant component of YST differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-020-00983-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271425PMC

Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2020 May 18. Epub 2020 May 18.

Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Background: Cancer stem cells (CSC) and their role in tumorigenesis of various solid tumors have been studied in past decades. Urothelial CSC were first identified 10 years ago and subsequent studies have been performed with the aim to identify reliable markers of CSC. So far, a few studies have investigated a relationship between CSC markers expression in urothelial carcinoma tissue and histopathological characteristics of the tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5507/bp.2020.017DOI Listing

Urethral carcinoma: A compilation of case studies and research findings.

Urol Case Rep 2020 Jul 3;31:101169. Epub 2020 Apr 3.

Medical College of Georgia, USA.

There are three major recognized histological types for primary urethral carcinoma (PUC). These include transitional cell carcinoma (55%), squamous cell carcinoma (21.5%), and adenocarcinoma (16. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2020.101169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154991PMC

[Large nested variant of urothelial carcinoma of urinary bladder: a clinicopathological analysis of five cases].

Zhonghua Bing Li Xue Za Zhi 2020 Apr;49(4):317-323

Department of Pathology, Zhejiang Provincial People's Hospital & People's Hospital of Hangzhou Medical College, Hangzhou 310014, China.

To investigate the clinicopathologic features, diagnosis and differential diagnosis of large nested variant of urothelial carcinoma (LNUC) of urinary bladder. The clinical and pathologic data of five cases of LNUC of urinary bladder diagnosed between January 2014 and December 2018 at the Department of Pathology, Zhejiang Provincial People's Hospital were analyzed by immunohistochemistry (IHC) and Sanger sequencing. The relevant literature was reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112151-20190721-00405DOI Listing

[Nerve-sparing robot-assisted laparoscopic radical cystectomy: Clinical application and effect].

Zhonghua Nan Ke Xue 2019 Sep;25(9):797-801

Gulou School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu 210008, China.

Objective: To investigate the clinical feasibility and effect of nerve-sparing robot-assisted laparoscopic radical cystectomy (NSRA-LSRC).

Methods: We retrospectively reviewed the clinical data on 12 cases of NSRA-LSRC performed from March 2016 to May 2018. The patients were aged 45 to 65 years old and all potent before surgery, with a mean IIEF-5 score of >17. Read More

View Article

Download full-text PDF

Source
September 2019

Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread.

Cancer Res Treat 2020 Mar 19. Epub 2020 Mar 19.

Department of Urology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea.

We present a rare case of urothelial carcinoma in situ (CIS), which invades the prostate and seminal vesicle (SV). A 70-year-old man underwent transurethral resection of bladder (TURB), and the pathologic examination revealed multiple CIS. Although the patient received intravesical bacillus Calmette-Guerin (BCG) therapy following TURB, recurrence of CIS was confirmed in the bladder and left distal ureter at 3 months following BCG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2020.002DOI Listing

Predictive value of prognostic nutritional index on tumor stage in patients with primary bladder cancer.

Arch Esp Urol 2020 Mar;73(2):132-139

Department of Urology. Istanbul Training and Research Hospital. University of Health Sciences. Istanbul. Turkey.

Objectives:  The aim of this study was to evaluate relationship between preoperative Prognostic Nutritional Index (PNI) values and tumor stage and to identify predictive value of PNI in patients with primary bladder cancer (BC).

Methods:  A total of 164 patients with primary bladder cancer were retrospectively analyzed using institutional bladder cancer database between January 2008 and January 2018. The PNI was calculated using preoperative blood sample results. Read More

View Article

Download full-text PDF

Source

A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive Bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.

J Urol 2020 Mar 2:101097JU0000000000000919. Epub 2020 Mar 2.

Department of Urology, Columbia University Irving Medical Center, New York, New York.

Purpose: For patients with bacillus Calmette-Guérin unresponsive or recurrent/relapsing nonmuscle invasive bladder cancer, multi-agent intravesical trials have been limited. In this study we investigate the safety of intravesical cabazitaxel, gemcitabine and cisplatin in the salvage setting.

Materials And Methods: This was a dose escalation, drug escalation trial for patients with bacillus Calmette-Guérin unresponsive or recurrent/relapsing nonmuscle invasive bladder cancer who declined or were ineligible for radical cystectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000919DOI Listing

Urine cytology suspicious for urothelial carcinoma: Prospective follow-up of cases using cytology and urine biomarker-based ancillary techniques.

Cancer Cytopathol 2020 Jul 21;128(7):460-469. Epub 2020 Feb 21.

Laboratory and Department of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Background: Urine cytology results that are suspicious for urothelial carcinoma (UC) are challenging. The objective of this study was to elucidate the clinical significance of such results in patients who have a negative cystoscopy.

Methods: In this prospective study, 83 patients who had urine cytology that was suspicious of UC and a negative cystoscopy underwent a second cystoscopy and urine evaluation by cytology, UroVysion fluorescence in situ hybridization (FISH) assay, FGFR3 (fibroblast growth factor receptor 3) and TERT (telomerase reverse transcriptase) mutations and an 8-gene expression classifier (GEC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncy.22252DOI Listing

HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.

Clin Genitourin Cancer 2019 Dec 13. Epub 2019 Dec 13.

Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan. Electronic address:

Introduction: Erb-b2 receptor tyrosine kinase 2 (ERBB2, also known as HER2) gene amplification or protein overexpression occurs in certain types of urothelial carcinomas. Molecular pathologic classification of urinary bladder cancer using immunohistochemistry has identified basal and luminal subtypes with differing prognoses, but the HER2 status of these subtypes has not been investigated. In addition, research on urothelial carcinoma of the renal pelvis and ureter (UCRPU) has not progressed because of its rarity, though its prognosis is worse than that of bladder cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.12.003DOI Listing
December 2019

Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.

Theranostics 2020 1;10(2):707-724. Epub 2020 Jan 1.

Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.

Muscle-invasive urinary bladder urothelial carcinoma (UBUC) is a lethal disease for which effective prognostic markers and potential therapy targets are still lacking. Previous array comparative genomic hybridization identified that 3q27 is frequently amplified in muscle-invasive UBUCs, one candidate proto-oncogene, (), mapped to this region. We therefore aimed to explore its downstream targets and physiological roles in UBUC progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.39018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929993PMC
January 2020

An improved mouse orthotopic bladder cancer model exhibiting progression and treatment response characteristics of human recurrent bladder cancer.

Oncol Lett 2020 Jan 2;19(1):833-839. Epub 2019 Dec 2.

Pharmaceutical and Healthcare Research Laboratories, FUJIFILM Corporation, Ashigarakami-gun, Kanagawa 258-8577, Japan.

Nonmuscle-invasive (superficial) bladder cancer is generally treated via surgical removal, followed by adjuvant therapy (bacillus Calmette-Guerin). However, bladder cancer can often recur, and in a substantial number of recurrent cases, the cancer progresses and metastasizes. Furthermore, residual microtumors following excision may lead to an increased risk of recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.11172DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924206PMC
January 2020

Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer.

Clin Adv Hematol Oncol 2019 Dec;17(12):697-707

Glickman Urological and Kidney Institute, Department of Urology, Cleveland Clinic, Cleveland, Ohio.

Bladder-sparing therapies for the treatment of nonmetastatic muscle-invasive bladder cancers are included in both American and European guidelines. Numerous treatment approaches have been described, including partial cystectomy, radiation monotherapy, and radical transurethral resection. However, the most oncologically favorable and well-studied regimen employs a multimodal approach that consists of maximal transurethral resection of the bladder tumor followed by concurrent radiosensitizing chemotherapy and radiotherapy. Read More

View Article

Download full-text PDF

Source
December 2019

DaBlaCa-11: Photodynamic Diagnosis in Flexible Cystoscopy-A Randomized Study With Focus on Recurrence.

Urology 2020 Mar 14;137:91-96. Epub 2019 Dec 14.

Department of Urology, Regional Hospital of West Jutland, Holstebro, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark; Department of Urology, Aarhus University Hospital, Aarhus, Denmark.

Objective: To examine whether photodynamic diagnosis (PDD) in addition to flexible cystoscopy in the outpatient clinic can reduce risk of tumor recurrence in patients with previous nonmuscle invasive bladder cancer. PDD is an optical technique that enhances the visibility of pathologic tissue and helps guidance tumor resection.

Methods: From February 2016 to December 2017, 699 patients from 3 urologic departments in Denmark were enrolled in a randomized controlled trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2019.12.002DOI Listing

Usefulness of narrow-band imaging in transurethral resection of bladder tumor: Early experience from a tertiary center in India.

South Asian J Cancer 2019 Oct-Dec;8(4):226-228

Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India.

Background: The current standard for diagnosis and treatment of urinary bladder cancer is transurethral resection of bladder tumor (TURBT) using white light guidance. Narrow band imaging (NBI) has emerged as a promising method for identifying additional bladder lesions. Various studies have been published to evaluate its sensitivity in identifying new lesions and its impact on decreasing recurrences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_367_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852624PMC
December 2019

Detection of carcinogen-induced bladder cancer by fluorocoxib A.

BMC Cancer 2019 Nov 27;19(1):1152. Epub 2019 Nov 27.

Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN, 37996, USA.

Background: Conventional cystoscopy can detect advanced stages of bladder cancer; however, it has limitations to detect bladder cancer at the early stages. Fluorocoxib A, a rhodamine-conjugated analog of indomethacin, is a novel fluorescent imaging agent that selectively targets cyclooxygenase-2 (COX-2)-expressing cancers.

Methods: In this study, we have used a carcinogen N-butyl-N-4-hydroxybutyl nitrosamine (BBN)-induced bladder cancer immunocompetent mouse B6D2F1 model that resembles human high-grade invasive urothelial carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-6366-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882158PMC
November 2019

Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder.

Am J Pathol 2020 02 15;190(2):323-332. Epub 2019 Nov 15.

Institute of Pathology, University Hospital Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany.

Bacillus Calmette-Guérin instillation after removal of the tumor is the first line of treatment for urothelial carcinoma in situ (CIS), the precursor lesion of most muscle-invasive bladder cancers. Bacillus Calmette-Guérin therapy fails in >50% of cases, and second-line radical cystectomy is associated with overtreatment and drastic lifestyle consequences. Given the need for alternative bladder-preserving therapies, we identified genomic alterations (GAs) in urothelial CIS having the potential to predict response to targeted therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2019.10.004DOI Listing
February 2020

[Novel approaches for transurethral en-bloc resection of large bladder tumors].

Urologiia 2019 Sep(4):105-111

Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow Russia.

Objective: to develop optimal techniques of en-bloc resection of large non-muscle invasive bladder tumors, determine the proper method of specimen extraction and assess the quality of specimens obtained by different techniques.

Materials And Methods: A total of 12 patients with primary cT1 bladder cancer underwent transurethral en-bloc resection between January 2018 and March 2019 were enrolled into the study. Tumor size ranged from 3. Read More

View Article

Download full-text PDF

Source
September 2019
1 Read

Lymphoepithelial - Like Carcinoma with Papillary Transitional Cell Carcinoma of the Urinary Bladder Associated with Carcinoma in situ Changes of the Urothelium; A Case Report and Review of Literature.

Iran J Pathol 2019 10;14(2):156-164. Epub 2019 Jun 10.

M.D, Pasteur Pathobiology Laboratory, Shiraz, Iran.

Lymphoepithelial - like carcinoma, is rarely recognized in the urinary bladder and less commonly occurs with papillary transitional cell carcinoma i.e. mixed pattern. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.30699/IJP.14.2.156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679663PMC

Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.

BMJ Open 2019 09 3;9(9):e022268. Epub 2019 Sep 3.

Urology, Northern Institute for Cancer Research, Newcastle upon Tyne, UK.

Introduction: Bladder cancer is the most frequently occurring tumour of the urinary system. Ta, T1 tumours and carcinoma in situ (CIS) are grouped as non-muscle invasive bladder cancer (NMIBC), which can be effectively treated by transurethral resection of bladder tumour (TURBT). There are limitations to the visualisation of tumours with conventional TURBT using white light illumination within the bladder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-022268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731798PMC
September 2019
1 Read

The Paris System for reporting urinary cytology in daily practice with emphasis on ancillary testing by multiprobe FISH.

J Clin Pathol 2020 Feb 29;73(2):90-95. Epub 2019 Aug 29.

Institute of Pathology, University Hospital Basel, Basel, Switzerland.

Aims: The Paris System (TPS) was introduced in the diagnostic routine with the goal to simplify and standardise diagnostic reporting of urinary cytology. The diagnostic categories of TPS are based on defined cytological criteria, with a focus on high-grade urothelial carcinoma (HGUC). While the categories 'negative for HGUC (NHGUC)' and 'HGUC' are straightforward, the categories 'atypical urothelial cells (AUC)' and 'suspicious of HGUC (SHGUC)' remain inconclusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2019-206109DOI Listing
February 2020
2 Reads

Amyloidosis of the bladder and association with urothelial carcinoma: report of 29 cases.

Hum Pathol 2019 11 16;93:48-53. Epub 2019 Aug 16.

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd Suite Room 8725, Los Angeles, CA 90048, USA. Electronic address:

The association of amyloidosis with certain neoplastic processes is well known. Amyloid uncommonly occurs in relationship with other epithelial neoplasms including urothelial carcinoma. Herein, we report 29 cases of amyloidosis in the bladder, 14 of which were found in relationship to urothelial carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.08.011DOI Listing
November 2019
3 Reads

Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?

Diagn Pathol 2019 Aug 16;14(1):91. Epub 2019 Aug 16.

Department of Pathology, The Ohio State University Medical Center, 410 W 10th Ave., 401 Doan Hall, Columbus, OH, 43210, USA.

Background: Urothelial carcinoma in situ (CIS) in the bladder can be difficult to diagnose due to factors including procedural artifact, minimal tissue sampled, therapy-related changes, and various CIS growth patterns. Prior data has demonstrated an increase in alpha-methylacyl-CoA-racemase (AMACR) in urothelial CIS, but there is no information on its utility for diagnosing difficult cases. The aim of this investigation was to assess the expression of AMACR that was ordered on equivocal bladder cases during clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-019-0871-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697956PMC
August 2019
2.411 Impact Factor

[Organ preservation by chemoradiation for bladder cancer].

Cancer Radiother 2019 Oct 7;23(6-7):732-736. Epub 2019 Aug 7.

Service d'urologie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.

When localized, the reference treatment of urothelial, muscle-invasive bladder tumours relies on radical cystectomy with reconstruction by enterocystoplasty if possible or Bricker bypass. Trimodal therapy combining transurethral resection of the tumour followed by concomitant chemotherapy may be considered as a therapeutic alternative to radical cystectomy in well-selected patients with unifocal tumours, stage T2, non-diverticular location, without in situ carcinoma or hydronephrosis and with macroscopically complete transurethral resection. The functional prognosis of the bladder and quality of life should be discussed with the patient as well as the need for salvage surgery for persistent tumour at a 45-Gy dose level, the latter being a highly unfavourable prognosis factor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canrad.2019.06.005DOI Listing
October 2019
1 Read

Condyloma Acuminatum of Urinary Bladder: Relation to Squamous Cell Carcinoma.

Am J Surg Pathol 2019 11;43(11):1547-1553

Departments of Pathology.

Condyloma acuminatum rarely occurs in the urinary bladder and is considered to be a risk factor for squamous cell carcinoma, although there are only a few publications with limited cases. We studied 51 cases of condyloma acuminatum of the urinary bladder from transurethral resections of the urinary bladder of 38 patients from the consult files of one of the authors. Transurethral resections of the urinary bladder were obtained from 25 males with a median age of 73 years (range: 41 to 87 y) and 13 females with a median age of 68 years (range: 30 to 86 y). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001339DOI Listing
November 2019
6 Reads

Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases.

Am J Surg Pathol 2019 12;43(12):1638-1643

Cleveland Clinic, Robert Tomsich Pathology and Laboratory Medicine Institute, Cleveland, OH.

Although there are 5 well-described morphologic patterns of (nonglandular) urothelial carcinoma in situ (CIS), we have encountered a novel pattern of flat urothelial carcinoma with plasmacytoid features characterized by a triad of morphologic findings including abnormal architecture with cellular rounding, enlarged nuclei with eccentric nuclear localization, and dense globular eosinophilic cytoplasm. A total of 23 cases of plasmacytoid CIS (mean age: 74.1 y, range: 58 to 91 y) were collected and reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001318DOI Listing
December 2019
4 Reads

Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer.

Anticancer Res 2019 Aug;39(8):4325-4328

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Background/aim: The significance of second transurethral resection (TUR), and identification of predictive factors for residual cancer remain unrevealed. This study aimed to find residual cancer and up-staging rates, as well as predictive factors for residual cancer, in patients who undergo second TUR for non-muscle-invasive bladder cancer (NMIBC).

Patients And Methods: Patients who underwent second TURs for NMIBC between 2015 and 2017, were included in the study and their clinicopathological characteristics were analyzed for predictors of residual cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13598DOI Listing
August 2019
2 Reads

Invasive high-grade urothelial carcinoma of the bladder, renal pelvis, ureter, and prostatic urethra arising in a background of urothelial carcinoma with an inverted growth pattern: a contemporary clinicopathological analysis of 91 cases.

Hum Pathol 2019 10 24;92:18-24. Epub 2019 Jul 24.

Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322; Department of Urology, Emory University School of Medicine, Atlanta, GA 30322; Department of Pathology, Veterans Affairs Medical Center, Decatur, GA 30033; Winship Cancer Institute of Emory University, Atlanta, GA 30322. Electronic address:

Urothelial carcinoma with an inverted/endophytic growth pattern can occasionally mimic inverted urothelial papilloma and pose diagnostic challenges when assessing the presence or absence of invasion. Making these distinctions is critical for guiding appropriate treatment and improving patient outcomes. Here we conducted one of the largest studies to date of invasive high-grade urothelial carcinoma arising in a background of urothelial carcinoma with an inverted growth pattern. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.07.005DOI Listing
October 2019

Hexaminolevulinate in the Management of Nonmuscle Invasive Bladder Cancer: A Meta-Analysis.

Photobiomodul Photomed Laser Surg 2019 Sep 24;37(9):551-558. Epub 2019 Jul 24.

1st Department of Urology, Medical University of Lodz, Lodz, Poland.

The objective of this study was to assess the effect of photodynamic diagnosis (PDD) using hexaminolevulinate on the diagnostic and therapeutic outcomes in nonmuscle invasive bladder cancer (NMIBC) patients. PubMed, Embase, and the Cochrane Library databases together with conference proceedings were searched. Recurrence-free survival was significantly higher at 3, 6, 9, and 12 months in the PDD groups than in the white light cystoscopy (WLC) groups with the cumulative values of differences in recurrence rates at different follow-up intervals ranging from 8% to 11%. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/photob.2019.4634
Publisher Site
http://dx.doi.org/10.1089/photob.2019.4634DOI Listing
September 2019
3 Reads

Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.

BMC Cancer 2019 Jul 19;19(1):716. Epub 2019 Jul 19.

Department of Urology, Affiliated Jiang-yin Hospital of the Southeast University Medical College, Jiang-yin, 214400, China.

Background: Assessing the prognostic significance of specific clinicopathological features plays an important role in surgical management after radical cystectomy. This study investigated the association between ten clinicopathological characteristics and cancer-specific survival (CSS) in patients with bladder cancer.

Methods: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, a literature search was conducted through the PubMed, EMBASE and Web of Science databases using appropriate search terms from the dates of inception until November 2018. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-019-5924-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642549PMC
July 2019
5 Reads

Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.

Virchows Arch 2019 Sep 12;475(3):349-356. Epub 2019 Jul 12.

Department of Pathology, The University of Alabama at Birmingham, WP Building, Suite P230, 619 19th Street South, Birmingham, AL, 35249-7331, USA.

The Cancer Genome Atlas project introduced genomic taxonomy of basal and luminal molecular subtypes in muscle invasive bladder cancer. Fewer studies have addressed the molecular classification in non-muscle invasive bladder cancer (NMIBC). Our aim is to assess the applicability of the proposed phenotypic classification for NMIBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-019-02618-5DOI Listing
September 2019
24 Reads
2.651 Impact Factor

Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center.

Ann Diagn Pathol 2019 Aug 13;41:124-128. Epub 2019 Jun 13.

Loyola University Medical Center, Department of Pathology and Laboratory Medicine, Maywood, IL, United States.

Introduction: Flat urothelial lesions fall into one of four diagnostic categories including urothelial carcinoma in-situ (CIS). There is morphologic overlap between the categories leading to immunohistochemistry (IHC) utilization in difficult cases. The purpose of this study was to examine the frequency, variation and utility of IHC use in bladder biopsy specimens over a 17 year period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.06.002DOI Listing
August 2019
6 Reads

Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guérin immunotherapy.

J Cancer Res Clin Oncol 2019 Aug 21;145(8):2131-2140. Epub 2019 Jun 21.

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.

Purpose: This study aimed at determining the relationship between classification according to the papillary tumor pattern of carcinoma in situ (CIS) of the bladder and prognosis, as this has not yet been well established.

Methods: This study comprised a consecutive cohort of 254 patients (primary CIS: 66 patients, stage Ta-CIS: 52 patients, and stage T1-CIS: 136 patients) with CIS-associated bladder cancer. We classified CIS according to the pathological pattern of papillary tumors and analyzed prognostic factors, including CIS classification, for progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02956-6DOI Listing
August 2019
18 Reads

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Eur Urol Oncol 2019 05 10;2(3):286-293. Epub 2018 Sep 10.

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

Background: Tumors that recur after bacillus Calmette-Guerin (BCG) therapy are considered to be of very high risk, and patients are often recommended to undergo radical cystectomy (RC). However, the nuances associated with the grade of tumor recurrence after BCG treatment are not well understood.

Objective: To characterize the pattern of bladder cancer progression and cancer-specific survival (CSS) in patients with recurrences dichotomized by low grade (LG) versus high grade (HG) after intravesical BCG treatment, and to assess the safety of continued bladder-sparing therapy in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.08.013DOI Listing
May 2019
5 Reads

Urothelial Carcinoma In Situ (CIS): New Insights.

Adv Anat Pathol 2019 Sep;26(5):313-319

Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.

Urothelial carcinoma in situ (CIS) is a high-grade noninvasive malignancy with a high tendency of progression. Although it is typically grouped with other nonmuscle invasive bladder cancers, its higher grade and aggressiveness make it a unique clinical entity. Urothelial CIS is histologically characterized by replacement of the urothelium by cells which fulfill the morphologic criteria of malignancy including nuclear pleomorphism, hyperchromasia, prominent nucleoli, and increased numbers of normal and abnormal mitoses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000239DOI Listing
September 2019
8 Reads

Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure CIS.

Minerva Urol Nefrol 2019 Aug 28;71(4):406-412. Epub 2019 May 28.

Department of Urology, Humanitas Clinic IRCCS, Rozzano, Milan, Italy.

Background: The aim of this study was to identify the predictive factors for progression defined as any event that shifted the management of the disease from a bladder sparing approach, by comparing patients with pure versus non-pure carcinoma in situ (CIS) of the bladder.

Methods: A retrospective analysis was carried out in consecutive patients affected by newly-diagnosed pure CIS and non-pure CIS (excluding cases with concomitant muscle invasive cancer). All patients were enrolled a in our institution from 1998 to 2010. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0393-2249.19.03254-5DOI Listing
August 2019
5 Reads
0.700 Impact Factor

SORLA regulates endosomal trafficking and oncogenic fitness of HER2.

Nat Commun 2019 05 28;10(1):2340. Epub 2019 May 28.

Turku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland.

The human epidermal growth factor receptor 2 (HER2) is an oncogene targeted by several kinase inhibitors and therapeutic antibodies. While the endosomal trafficking of many other receptor tyrosine kinases is known to regulate their oncogenic signalling, the prevailing view on HER2 is that this receptor is predominantly retained on the cell surface. Here, we find that sortilin-related receptor 1 (SORLA; SORL1) co-precipitates with HER2 in cancer cells and regulates HER2 subcellular distribution by promoting recycling of the endosomal receptor back to the plasma membrane. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-10275-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538630PMC
May 2019
26 Reads

Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer Within a Large, Diverse Integrated Delivery System.

Urology 2019 Sep 24;131:93-103. Epub 2019 May 24.

Department of Urology, Southern California Permanente Medical Group, Riverside, CA.

Objectives: To examine treatment variability, disparities, and quality among newly diagnosed nonmuscle invasive bladder cancer (NMIBC) patients, and to identify factors associated with treatment use in a large, diverse integrated delivery system.

Methods: Retrospective cohort study of 5386 NMIBC patients diagnosed between January 2001 and June 2015 within Kaiser Permanente Southern California. Electronic health data were used to identify treatment outcomes and patient, provider, and tumor characteristics. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00904295193044
Publisher Site
http://dx.doi.org/10.1016/j.urology.2019.03.035DOI Listing
September 2019
5 Reads

Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

J Urol 2019 11 9;202(5):920-926. Epub 2019 Oct 9.

Mayo Clinic, Rochester, Minnesota.

Purpose: Single center studies have shown that positive UroVysion® fluorescence in situ hybridization results were associated with recurrence of nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. Our goal was to validate these findings.

Materials And Methods: We performed a prospective, multicenter diagnostic trial to determine whether the fluorescence in situ hybridization test could predict recurrence or progression in patients with primary high grade nonmuscle invasive bladder cancer who were scheduled to receive bacillus Calmette-Guérin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000355DOI Listing
November 2019
9 Reads

Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.

Cochrane Database Syst Rev 2019 05 14;5:CD013336. Epub 2019 May 14.

Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Korea, South.

Background: In the treatment of urothelial carcinoma of the bladder, we are currently uncertain of the benefits and harms of standard pelvic lymph node dissection (PLND) compared to extended PLND.

Objectives: To assess the effects of extended versus standard PLND in patients undergoing cystectomy to treat muscle-invasive (cT2 and cT3) and treatment-refractory, non-muscle-invasive (cT1 with or without carcinoma in situ) urothelial carcinoma of the bladder.

Search Methods: We performed a comprehensive literature search using multiple databases (PubMed, Embase, Cochrane Controlled Trials, Web of Science, and LILACS), trial registries, and conference proceedings published up to April 29, 2019, with no restrictions on the language or status of publication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD013336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528183PMC
May 2019
9 Reads

BK polyomavirus and urothelial carcinoma: Experience at a tertiary care centre in India with review of literature.

Ann Diagn Pathol 2019 Jun 23;40:77-80. Epub 2019 Apr 23.

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. Electronic address:

Introduction: BK polyomavirus is ubiquitous and remains dormant in the urothelial tract, reactivating and replicating in the immunocompromised state especially in the setting of post-renal transplantation where it is believed to be directly oncogenic based on recent reports. Its oncogenic role in the immunocompetent host is controversial. This study aimed to investigate the association of BK polyomavirus in Urothelial Carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.04.006DOI Listing
June 2019
4 Reads

Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.

Hum Pathol 2019 08 6;90:1-7. Epub 2019 May 6.

Urology, The Johns Hopkins Medical Institutions, , Baltimore, MD 21231, USA; Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD 21231, USA; Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. Electronic address:

Carcinoma in situ (CIS) is difficult to visualize with white light cystoscopy (WLC), whereas blue light cystoscopy (BLC) using photosensitizing agents improves detection rates. We retrospectively reviewed transurethral biopsies of bladder tumors in which both WLC and BLC evaluations were performed (n = 135 samples from 79 patients). Biopsies were classified based on the presence/absence of fluorescence under BLC and the final pathological report (CIS/benign/atypical). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.04.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696917PMC
August 2019
6 Reads

A Review of Urine Ancillary Tests in the Era of the Paris System.

Acta Cytol 2020 6;64(1-2):182-192. Epub 2019 May 6.

Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA,

Aside from its diagnostic importance, urinary tract endoscopy is an uncomfortable, expensive, and time-consuming procedure. Patients with a history of urothelial carcinoma remain at an increased risk for recurrence and the development of de novo disease; most have had exposure to carcinogenic risk factors for decades prior to their first diagnosis that have bathed the entire urothelial tract. Consequently, monitoring these patients over their lifetime has made urothelial carcinoma one of the most expensive cancers for the US healthcare system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499027DOI Listing
January 2020
2 Reads

Propensity-Matched Survival Analysis of Upper Urinary Tract Urothelial Carcinomas between End-Stage Renal Disease with and without Kidney Transplantation.

Biomed Res Int 2019 1;2019:2979142. Epub 2019 Apr 1.

Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Urothelial carcinoma is the most common cancer following kidney transplantation (KT) in Taiwan. Unusual presentation of upper urinary tract urothelial carcinoma (UTUC) is noted in Taiwan and China. As the post-KT-UTUC oncological course is not fully understood, the aim of this study is to identify postulated significant differences for the clinical cancer course of UTUC among end-stage renal disease (ESRD) patients with and without KT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/2979142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463629PMC
August 2019
4 Reads

Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients.

Hum Pathol 2019 08 3;90:27-36. Epub 2019 May 3.

Indiana University, Department of Pathology and Laboratory Medicine, Indianapolis, IN 46202.

Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.04.012DOI Listing
August 2019
13 Reads

Robot-Assisted Radical Cystectomy with Intracorporeal Orthotopic Ileal Neobladder: A Safe Strategy in Elderly Patients? Results of Propensity Score Matching in a Single High-Volume Center.

Surg Technol Int 2019 May;34:302-309

Robotic Urology and Mini Invasive Urologic Surgery Unit, Policlinico Abano TermeAbano Terme Padua (PD), Italy.

Aim: To compare surgical, functional and early survival outcomes for robot-assisted radical cystectomy (RARC) with intracorporeal orthotopic neobladder (ONB) reconstruction in patients age = 75 y to those in patients age < 75 y using Propensity Score Matching.

Methods: We collected data from 15 patients age = 75 y from among 60 consecutive RARC with ONB reconstruction performed at our institution from January 2015 to July 2018. All procedures were performed by a single surgeon after modular training under the supervision of a skilled surgeon. Read More

View Article

Download full-text PDF

Source
May 2019
7 Reads

Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients

Asian Pac J Cancer Prev 2019 Apr 29;20(4):1271-1273. Epub 2019 Apr 29.

Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, Japan.

Objective: UroVysion (Abbott Molecular, Inc., Illinois, USA) is based on multicolor fluorescence in situ hybridization (FISH). It has been used successfully in the USA following its Food and Drug Administration approval in 2001. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2019.20.4.1271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948889PMC
April 2019
8 Reads

Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.

Mod Pathol 2019 10 25;32(10):1544-1550. Epub 2019 Apr 25.

Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.

Noninvasive approaches for early detection of bladder cancer are actively being investigated. We recently developed a urine- based molecular assay for the detection and surveillance of bladder neoplasms (UroSEEK). UroSEEK is designed to detect alterations in 11 genes that include most common genetic alterations in bladder cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0276-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872189PMC
October 2019
11 Reads

Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer.

Urology 2019 Aug 12;130:93-98. Epub 2019 Apr 12.

Department of Pathology, Hospital University La Fe, Valencia, Spain.

Objetives: To assess if "tumor budding" (TB) behaves as a poor prognostic factor in muscle-invasive bladder carcinoma (MIBC). TB is the presence of tumor cells isolated or in small groups of fewer than 5 cells located at the tumor invasion front.

Material And Methods: Retrospective study of 106 patients with MIBC who underwent radical cystectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2019.04.006DOI Listing
August 2019
25 Reads